X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (605) 605
Publication (53) 53
Book Review (13) 13
Book Chapter (6) 6
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trabectedin (586) 586
humans (360) 360
index medicus (358) 358
oncology (355) 355
chemotherapy (229) 229
female (205) 205
sarcoma (166) 166
cancer (158) 158
middle aged (133) 133
adult (125) 125
dioxoles - therapeutic use (120) 120
male (119) 119
tetrahydroisoquinolines - therapeutic use (112) 112
aged (110) 110
pharmacology & pharmacy (109) 109
antineoplastic agents, alkylating - therapeutic use (103) 103
ecteinascidin-743 (99) 99
sarcoma - drug therapy (97) 97
et-743 (96) 96
phase-ii (95) 95
ovarian cancer (92) 92
animals (90) 90
dioxoles - administration & dosage (89) 89
soft-tissue sarcoma (88) 88
tetrahydroisoquinolines - administration & dosage (88) 88
dioxoles - adverse effects (85) 85
soft tissue sarcoma (80) 80
tumors (80) 80
tetrahydroisoquinolines - adverse effects (79) 79
care and treatment (76) 76
research (76) 76
pegylated liposomal doxorubicin (75) 75
treatment outcome (73) 73
dioxoles - pharmacology (72) 72
doxorubicin (72) 72
drug therapy (68) 68
antitumor-activity (67) 67
disease-free survival (66) 66
leiomyosarcoma (63) 63
liposarcoma (62) 62
medicine & public health (60) 60
antineoplastic agents, alkylating - adverse effects (58) 58
tetrahydroisoquinolines - pharmacology (58) 58
metastasis (57) 57
analysis (54) 54
antineoplastic combined chemotherapy protocols - therapeutic use (54) 54
sarcoma - pathology (54) 54
ovarian neoplasms - drug therapy (53) 53
tetrahydroisoquinolines (53) 53
antineoplastic agents, alkylating - pharmacology (52) 52
ifosfamide (52) 52
cancer therapies (49) 49
efficacy (49) 49
soft-tissue sarcomas (49) 49
clinical trials (48) 48
neoplasms - drug therapy (48) 48
patients (47) 47
gemcitabine (46) 46
young adult (46) 46
antineoplastic agents - therapeutic use (44) 44
retrospective studies (43) 43
aged, 80 and over (42) 42
safety (42) 42
hematology, oncology and palliative medicine (41) 41
pharmacology/toxicology (40) 40
antineoplastic agents, alkylating - administration & dosage (39) 39
cell line, tumor (39) 39
trial (39) 39
dioxoles - pharmacokinetics (37) 37
homologous recombination (37) 37
mice (37) 37
therapy (37) 37
dna (35) 35
randomized phase-ii (35) 35
yondelis (35) 35
health aspects (34) 34
solid tumors (34) 34
antineoplastic agents - pharmacology (33) 33
apoptosis (33) 33
doxorubicin - administration & dosage (33) 33
neoplasms. tumors. oncology. including cancer and carcinogens (33) 33
tetrahydroisoquinolines - pharmacokinetics (33) 33
toxicity (33) 33
european organization (32) 32
cancer research (31) 31
deoxyribonucleic acid--dna (31) 31
dna repair (31) 31
metastatic liposarcoma (31) 31
obstetrics & gynecology (31) 31
survival (31) 31
adolescent (30) 30
anthracyclines (30) 30
antitumor (30) 30
ecteinascidin-743 et-743 (30) 30
leiomyosarcoma - drug therapy (29) 29
mechanism (29) 29
prognosis (29) 29
docetaxel (28) 28
article (27) 27
continuous intravenous-infusion (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (580) 580
French (8) 8
German (6) 6
Spanish (5) 5
Polish (4) 4
Russian (4) 4
Japanese (2) 2
Chinese (1) 1
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Controlled Release, ISSN 0168-3659, 04/2018, Volume 276, pp. 140 - 149
Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 11/2018, Volume 36, Issue 31, pp. 3134 - 3134
PurposeThis multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients... 
TRABECTEDIN | ONCOLOGY | PM01183 | DNA | ORIGINAL REPORTS
Journal Article
The Oncologist, ISSN 1083-7159, 01/2018, Volume 23, Issue 1, pp. 62 - 70
Background Alveolar soft part sarcoma (ASPS) is an exceedingly rare and orphan disease, without active drugs approved in the front line. Pazopanib and... 
Chemotherapy | Sarcoma | Trabectedin | Alveolar soft part sarcoma | Pazopanib | SOLID TUMORS | EFFICACY | TISSUE SARCOMA | PHASE-II | ANTITUMOR-ACTIVITY | METASTATIC LIPOSARCOMA | ONCOLOGY | SUNITINIB | MUSCULOSKELETAL ONCOLOGY GROUP | TUMOR MICROENVIRONMENT | Sarcomas
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1995 - 2002
Abstract Background Treatment options for soft tissue sarcoma (STS) patients aged ≥65 years (elderly) can be limited by concerns regarding the increased risk... 
soft tissue sarcomas | elderly | trabectedin | Original
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 06/2017, Volume 44, Issue 6, pp. 463 - 467
Journal Article
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 28, pp. 19929 - 19944
Therapy-induced senescence is a major cellular response to chemotherapy in solid tumors. Senescent tumor cells acquire a secretory phenotype, or SASP, and... 
Therapy-induced senescence | NF-kappaB | Trabectedin | SASP | Apoptosis
Journal Article
Nowotwory, ISSN 0029-540X, 11/2018, Volume 68, Issue 3, pp. 127 - 131
Journal Article
Oncology (Switzerland), ISSN 0030-2414, 12/2018, Volume 95, Issue 1, pp. 11 - 20
Journal Article
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ISSN 0006-291X, 05/2019, Volume 513, Issue 2, pp. 326 - 331
Recurrent osteosarcoma is a chemotherapy-resistant disease. Individualized precision therapy is needed for this disease. Toward this goal, we have developed... 
Irinotecan | BIOPHYSICS | MECHANISM | Osteosarcoma | Patient-derived othotopic xenograft | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOXORUBICIN | PDOX | Trabectedin | Combination therapy | CELL
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 11/2018, Volume 24, Issue 21, pp. 5233 - 5238
Purpose: The prognosis for patients with refractory softtissue sarcoma (STS) is dismal. Anlotinib has previously shown antitumor activity on STS in preclinical... 
DOXORUBICIN-BASED CHEMOTHERAPY | 1ST-LINE TREATMENT | LIPOSARCOMA | ONCOLOGY | 2-STAGE DESIGNS | CLINICAL-TRIALS | DOUBLE-BLIND | CONTROLLED PHASE-3 TRIAL | OPEN-LABEL | TRABECTEDIN | PART SARCOMA
Journal Article
ANNALS OF ONCOLOGY, ISSN 0923-7534, 09/2018, Volume 29, Issue 9, pp. 1995 - 2002
Background: Treatment options for soft tissue sarcoma (STS) patients aged >= 65 years (elderly) can be limited by concerns regarding the increased risk of... 
soft tissue sarcomas | SAFETY | elderly | DOXORUBICIN | IFOSFAMIDE | FAILURE | TRIAL | METASTATIC LIPOSARCOMA | ONCOLOGY | trabectedin | SOFT-TISSUE SARCOMA | AGE | SCHEDULES
Journal Article
Expert Opinion on Therapeutic Targets, ISSN 1472-8222, 08/2019, Volume 23, Issue 8, pp. 651 - 654
Journal Article
Journal Article